Welcome to our dedicated page for C4 Therapeutics news (Ticker: CCCC), a resource for investors and traders seeking the latest updates and insights on C4 Therapeutics stock.
C4 Therapeutics, Inc. reports developments tied to its clinical-stage targeted protein degradation business, including oncology programs designed with its TORPEDO® platform. Recurring company updates cover cemsidomide, an oral IKZF1/3 degrader being studied in relapsed/refractory multiple myeloma, as well as broader degrader-medicine research intended to address disease-causing proteins.
Company news also includes collaboration activity, such as its Roche agreement for degrader-antibody conjugates, along with clinical disclosures, operating and financial results, conference participation, equity inducement grants, and other governance matters under Nasdaq rules.
C4 Therapeutics (Nasdaq: CCCC) announced participation in the Bank of America Securities Precision Oncology Conference 2022. The event will occur on October 3, 2022, at 9:50 a.m. ET. C4T focuses on advancing targeted protein degradation science to develop innovative small-molecule medicines aimed at improving patient outcomes in oncology. The presentation will be available via live webcast on the company's website, with an archived replay accessible for 30 days post-event. C4T is leveraging its TORPEDO® platform to tackle challenging diseases.
C4 Therapeutics (Nasdaq: CCCC) reported a 40% increase in total revenue to $13.8 million for Q2 2022, up from $9.8 million in Q2 2021, driven by collaboration agreements. The company incurred a net loss of $27.4 million, leading to a net loss per share of $0.56. C4T continues to advance its pipeline with CFT7455 and CFT8634 in Phase 1/2 trials. The company maintains a strong cash position of $397.8 million, projected to fund operations through the end of 2024.
C4 Therapeutics, Inc. (Nasdaq: CCCC) has appointed Dr. Laura Bessen and Dr. Donna Grogan to its board of directors, enhancing its leadership as it advances targeted protein degradation science. Dr. Bessen brings over 20 years in medical affairs, having launched 11 products at Bristol Myers Squibb. Dr. Grogan, an expert in drug development, has held leadership roles at multiple biopharmaceutical firms. Their appointments signify C4T's commitment to innovative therapies in oncology as it progresses multiple programs in clinical trials.
C4 Therapeutics (Nasdaq: CCCC) announced the dosing of the first patient in its Phase 1/2 clinical trial for CFT8634, a targeted treatment for SMARCB1-perturbed cancers, including synovial sarcoma. This BiDAC™ degrader targets BRD9, deemed 'undruggable.' The trial will focus on CFT8634's safety, tolerability, and anti-tumor activity, enrolling approximately 90 patients. CFT8634 has received orphan drug designation from the FDA, marking a significant advancement in C4T's oncology pipeline and potentially offering new options for patients with limited therapies.
C4 Therapeutics (Nasdaq: CCCC) reported Q1 2022 financial results, with total revenue of $7.7 million compared to $7.4 million in Q1 2021. R&D expenses rose to $26.2 million, up from $20.5 million year-over-year. The net loss increased to $31.6 million or $0.65 per share, compared to a $21.0 million loss in the prior year. As of March 31, 2022, cash, cash equivalents, and marketable securities totaled $421.7 million, expected to fund operations until late 2024. The company continues dose optimization trials for CFT7455 and has initiated a Phase 1/2 trial for CFT8634.
C4 Therapeutics (Nasdaq: CCCC) announced promising early data from its Phase 1/2 trial of CFT7455, a targeted protein degrader aimed at treating multiple myeloma and non-Hodgkin's lymphomas. The trial demonstrated significant drug activity, with some patients showing reductions in serum free light chains by up to 78%. However, dose-limiting toxicities were noted, including Grade 4 neutropenia. The trial aims to optimize dosing to enhance the therapeutic index as patient enrollment continues. A conference to discuss these findings is scheduled for today.
C4 Therapeutics, Inc. (Nasdaq: CCCC) has appointed Utpal Koppikar as an independent board member and chair of the Audit Committee. Koppikar, currently CFO at Atara Biotherapeutics, brings extensive financial expertise and leadership in the biotechnology sector. The appointment aims to enhance corporate governance and support C4T's growth strategies in targeted protein degradation. Following this change, Dr. Elena Prokupets has retired from the board. C4T is advancing its novel degrader medicines using its TORPEDO® platform to transform patient care.
C4 Therapeutics (Nasdaq: CCCC) announced that the FDA has granted orphan drug designation to CFT8634 for treating soft tissue sarcoma. This designation benefits drug development for rare diseases affecting fewer than 200,000 people in the U.S., offering financial incentives and potential market exclusivity. CFT8634 targets BRD9, considered an 'undruggable' target, demonstrating efficacy in preclinical models. The company aims to begin Phase 1/2 trials in the first half of 2022, addressing a critical need as current treatment options for synovial sarcoma patients are limited.
C4 Therapeutics (Nasdaq: CCCC) has announced that its clinical data from the ongoing Phase 1/2 trial of CFT7455 will be presented as a late-breaker poster at the AACR Annual Meeting 2022 from April 8-13 in New Orleans. This includes three oral presentations on the novel IKZF1/3 degrader, along with additional preclinical data on CFT8634 and CFT1946. An investor webcast is scheduled for April 8, 2022, at 2 PM ET to discuss these findings, showcasing the company's commitment to advancing targeted protein degradation in oncology.
C4 Therapeutics reported significant advancements and financial results for 2021, including total revenue of $45.8 million, up from $33.2 million in 2020, primarily due to collaboration agreements. Despite a net loss of $83.9 million, the net loss per share improved to $1.82 from $5.83. The company anticipates its cash reserves of $451.5 million will sustain operations through 2024. Upcoming presentations at the AACR Annual Meeting will showcase clinical data on the CFT7455 trial for hematologic malignancies and pre-clinical data on novel candidates.